LSP reports first closing of dementia fund
European life sciences investors LSP has closed a new fund to fight dementia at 50m.
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1191 entries already.
European life sciences investors LSP has closed a new fund to fight dementia at 50m.
French Valneva SE announced it is in advanced discussions with the European Commission (EC) for the supply of up to 60 million doses of its COVID-19 vaccine, VLA2001.
Immuno-oncology specialist Immunocore plc announced the completion of a $75m Series C private financing round.
Following a recommendation by the European Medicines Agency (EMA), the European Commission has approved a second vaccine against the novel coronavirus SARS-CoV-2.
Italian Angelini Pharma and Swiss CNS disease specialist Arvelle Therapeutics have entered into a definitive merger agreement.
University of Birmingham researchers have invented a COVID-19 RNA test that reduces testing time from 30 minutes to under five, and delivers accurate results.
Following a rapid FDA approval, the European drug authority EMA has recommended to conditionally approve BioNTechs mRNA vaccine BNT162b2 in the EU.
Only two and a half months after its launch, the EU bioecocomy venture capital fund ECBF has doubled the volume of its first closing.
Danish Novo Holdings has founded Hemab ApS that is focussed on fighting orphan bleeding disorders by bi-specific antibodies.
Austria has needed a biotech association for a long time. In just two months, entrepreneurs have launched Biotech Austria.